Keele Research Repository

Article

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Burden, AD, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Study Group, BADBIR (2019) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34 (4). 769 - 778.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD and Study Group, BADBIR (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181 (6). 1265 - 1271.

Dand, N, Duckworth, M, Baudry, D, Russell, A, Curtis, CJ, Lee, SH, Evans, I, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Alsharqi, A, Becher, G, Burden, AD, Goodwin, RG, McKenna, K, Murphy, R, Perera, GK, Rotarescu, R, Wahie, S, Wright, A, Reynolds, NJ, Warren, RB, Griffiths, CEM, Smith, CH, Simpson, MA, Barker, JN, Study Group, BADBIR, Study Group, BSTOP and Consortium, PSORT (2018) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143 (6). 2120 - 2130.

Warren, RB, Marsden, A, Tomenson, B, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, Consortium, PSORT and Study Group, BADBIR (2018) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180 (5). 1069 - 1076.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Smith, CH, Hampton, PJ, Lunt, M, McElhone, K, Warren, RB, Yiu, ZZN, Griffiths, CEM, Burden, AD and Study Group, BADBIR (2018) Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154 (5). 581 - 588.

Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.